Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
MSD Going Full Out for Sakigake-Designated Pembrolizumab, Poised to Bolster Oncology Force
MSD K.K. is devoting its intensive resources and efforts to its anti-PD-1 antibody pembrolizumab, which is now under regulatory review in Japan, as it gears up for its launch and a string of planned indication expansions, the company’s executives said…
To read the full story
Related Article
- MSD Japan President Pins High Hopes on Keytruda Growth in 2017 after 7.8% Sales Dip
April 5, 2017
- Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
March 2, 2016
- MSD Seeks Lung Cancer Indication for Pembrolizumab in Japan
March 1, 2016
- MSD Seeks Japan Approval for Pembrolizumab for Melanoma
December 24, 2015
- MSD Japan Sales Down 14%, Januvia Sags 6.7%
March 6, 2015
BUSINESS
- Astellas Sees Xtandi Patent Cliff a “Critical Phase,” Steps Up Board Oversight via EPM
December 10, 2025
- PeptiDream Hits Milestone with Asahi Kasei Collaboration
December 10, 2025
- Eisai’s Leqembi Added to China Commercial Insurance Drug List
December 10, 2025
- Drug Makers, Wholesalers See No Major Disruptions after Aomori Quake
December 10, 2025
- SanBio Clears Hurdle for Akuugo Shipments, Heads to Reimbursement Talks
December 10, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…